Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ivermectin + pyrantel
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Ivermectin + pyrantel** is an oral combination anthelmintic (anti-parasitic) drug formulation primarily used in dogs to prevent heartworm disease (Dirofilaria immitis) and to treat and control roundworm (Toxocara canis, Toxascaris leonina) and hookworm (Ancylostoma caninum, Uncinaria stenocephala, Ancylostoma braziliense) infections. Ivermectin is a macrocyclic lactone that binds to glutamate-gated chloride ion channels in nematode nerve and muscle cells, causing paralysis and death of the parasites. Pyrantel, a tetrahydropyrimidine, acts as a depolarizing neuromuscular-blocking agent, resulting in paralysis of susceptible parasites, which are expelled by normal peristalsis. This combination is used as a monthly chewable for prevention and parasite control in veterinary medicine[1][2][4][5][6][9][12].
- Brand names
- Heartgard PlusTri-Heart PlusIverhart Plus
- Other names
- ivermectin + pyrantel pamoateivermectin and pyrantel
02
Targets
P2RX4 (P2X Purinoceptor 4)FXR (Farnesoid x-activated receptor)Glycine receptorGluCl (Glutamate-gated chloride channel)CHRNA7 (α7 nicotinic receptor)GABAA (Gamma-aminobutyric acid receptor)
Beyond the preview
Go deeper on ivermectin + pyrantel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ivermectin + pyrantel.